A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

NCT05471648 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection
DRUG: Perjeta (EU origin) 420 mg in 14 mL Injection
DRUG: Perjeta (US origin) 420 mg in 14 mL Injection

Sponsor

EirGenix, Inc.

Collaborators

[object Object]